Erlotinib Completed Phase 2 Trials for Carcinoma NOS Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00737243Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site